Quick Answer
UroGen Pharma Ltd. reported Stockholders Equity of -$105.47 million for fiscal year 2025.
UroGen Pharma Ltd. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$105.47M | -1098.2% |
| 2024 | -$8.80M | +86.5% |
| 2023 | -$65.21M | +27.0% |
| 2022 | -$89.36M | -1162.2% |
| 2021 | $8.41M | -91.3% |
| 2020 | $96.36M | -46.6% |
| 2019 | $180.30M | +100.1% |
| 2018 | $90.09M | +31.5% |
| 2017 | $68.52M | +320.2% |
| 2016 | $16.31M | +0.2% |
| 2015 | $16.28M | +414.7% |
| 2014 | $3.16M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$115.41M | -552.3% | -23.6% |
| June 30, 2025 | -$93.38M | -408.0% | -101.0% |
| March 31, 2025 | -$46.46M | -15.8% | -427.8% |
| December 31, 2024 | -$8.80M | +86.5% | -134.5% |
| September 30, 2024 | $25.52M | +160.8% | -15.8% |
| June 30, 2024 | $30.31M | +121.9% | +175.5% |
| March 31, 2024 | -$40.13M | +65.6% | +38.5% |
| December 31, 2023 | -$65.21M | +27.0% | -55.3% |
- UroGen Pharma Ltd. showed a decrease of -1098.2% in Stockholders Equity compared to the prior fiscal year.
- Over the 2014–2025 period, UroGen Pharma Ltd.’s stockholders equity has declined by 3434.6% (from $3.16 million to -$105.47 million).
- The most recent figure is from UroGen Pharma Ltd.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: